BNP/CALL/ASTRAZENECA/10500/0.1/20.12.24 Stock

DE000PC3BU33

Market Closed - Boerse Frankfurt Warrants 11:21:00 2024-06-07 am EDT
2.94 ^EUR	0.00%

Current month	+14.84%
1 month	+16.67%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart ASTRAZENECA PLC

Chart BNP/CALL/ASTRAZENECA/10500/0.1/20.12.24

Latest news about ASTRAZENECA PLC

I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer	Jun. 07	AQ
ASTRAZENECA : JP Morgan reiterates its Buy rating	Jun. 07	ZD
Pharma Company Astrazeneca Withdrawing Covid Vaccine Because It's Outdated - Not 'After Admitting to Dangerous Side Effect'	Jun. 06	AQ
Astrazeneca completes £1.5bn Fusion Pharmaceuticals deal	Jun. 06	AQ

More news

Quotes 5-day view

Date	Price	Change
24-06-07	2.94	0.00%
24-06-06	2.94	+0.34%
24-06-05	2.93	+5.02%
24-06-04	2.79	+1.82%
24-06-03	2.74	+7.03%

Real-time Boerse Frankfurt Warrants

Last update June 07, 2024 at 11:21 am EDT

More quotes

Static data

Product type	Plain-Vanilla-Warrants
Buy / Sell	CALL
Underlying	ASTRAZENECA PLC
Issuer	BNP Paribas
WKN	PC3BU3
ISIN	DE000PC3BU33
Date issued	2024-01-16
Strike	10,500 p
Maturity	2024-12-20 (195 Days)
Parity	10 : 1
Emission price	1.44 €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Highest since issue	2.95 €
Lowest since issue	0.61 €
Spread	0.02 €
Spread %	0.68%

Company Profile

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (4.4%). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).

Sector

More about the company